Technology and products: cancer: Quest Diagnostics

Article Abstract:

Teterboro, NJ-based Quest Diagnostics Inc. is launching a new service to perform high-risk human papillomavirus (HPV) DNA testing for women with inconclusive results on their ThinPrep Pap Test for cervical cancer or its precursors.

Quest Diagnostics Inc., DGX

---

Immunoassay: NMP179 may reduce uncertainty of mildly abnormal pap smears

Article Abstract:

Matritech's new test (NMP179) may reduce the uncertainty, apprehension and cost associated with millions of mildly abnormal Pap smears, according to a new report.

Matritech Inc., NMPS

---

Neopath: Neopath's Autopap System succeeds in Kaiser Permanente clinical study

Article Abstract:

The Neopath AutoPap System significantly outperforms current pap tests, according to a study by Kaiser Permanente Medical Group.

Neopath Inc., NPTH

Similar abstracts:

• Abstracts: Cancer therapy management-current and emerging in vitro diagnostic technologies. Cancers in women: 2000-2020 will be a decade of change
• Abstracts: Infectious disease: Epitope: activists demand FDA approval of HIV saliva test. Infectious disease: Virco: HIV resistance test

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.